An Analysis of Time Trends in Breast and Prostate Cancer Mortality Rates in Lithuania, 1986-2020

Overview

Journal BMC Public Health

Publisher Biomed Central

Specialty Public Health

Date 2022 Sep 23

PMID 36151551

Authors

Ruta Everatt

Daiva Gudaviciene

Affiliations

Soon will be listed here.

Abstract

Background: Breast cancer (BC) and prostate cancer (PC) mortality rates in Lithuania remain comparatively high despite the ongoing BC and PC screening programmes established in 2006. The aim of this study was to investigate time trends in BC and PC mortality rates in Lithuania evaluating the effects of age, calendar period of death, and birth-cohort over a 35-year time span.

Methods: We obtained death certification data for BC in women and PC in men for Lithuania during the period 1986-2020 from the World Health Organisation database. Age-standardised mortality rates were analysed using Joinpoint regression. Age-period-cohort models were used to assess the independent age, period and cohort effects on the observed mortality trends.

Results: Joinpoint regression analysis indicated that BC mortality increased by 1.6% annually until 1996, and decreased by - 1.2% annually thereafter. The age-period-cohort analysis suggests that temporal trends in BC mortality rates could be attributed mainly to cohort effects. The cohort effect curvature showed the risk of BC death increased in women born prior to 1921, remained stable in cohorts born around 1921-1951 then decreased; however, trend reversed in more recent generations. The period effect curvature displayed a continuous decrease in BC mortality since 1991-1995. For PC mortality, after a sharp increase by 3.0%, rates declined from 2007 by - 1.7% annually. The period effect was predominant in PC mortality, the curvature displaying a sharp increase until 2001-2005, then decrease.

Conclusions: Modestly declining recent trends in BC and PC mortality are consistent with the introduction of widespread mammography and PSA testing, respectively, lagging up to 10 years. The study did not show that screening programme introduction played a key role in BC mortality trends in Lithuania. Screening may have contributed to favourable recent changes in PC mortality rates in Lithuania, however the effect was moderate and limited to age groups < 65 years. Further improvements in early detection methods followed by timely appropriate treatment are essential for decreasing mortality from BC and PC.

Citing Articles

Exploring Prostate Cancer Incidence Trends and Age Change in Cancer Registration Areas of Jiangsu Province, China, 2009 to 2019.

Zhou H, Hong X, Miao W, Wang W, Wang C, Han R Curr Oncol. 2024; 31(9):5516-5527.

PMID: 39330036 PMC: 11431764. DOI: 10.3390/curroncol31090408.

Incidence-Based Breast Cancer Mortality Trends in Estonia Before and After the Introduction of Organized Mammography Screening: A Register-Based Study.

Baburin A, Veerus P, Lang K, Innos K Cancer Control. 2024; 31:10732748241266491.

PMID: 39092882 PMC: 11297520. DOI: 10.1177/10732748241266491.

Novel chimeric antigen receptor T cell-based immunotherapy: a perspective for triple-negative breast cancer.

Geng P, Chi Y, Yuan Y, Yang M, Zhao X, Liu Z Front Cell Dev Biol. 2023; 11:1158539.

PMID: 37457288 PMC: 10339351. DOI: 10.3389/fcell.2023.1158539.

References

Gondos A, Krilaviciute A, Smailyte G, Ulys A, Brenner H . Cancer surveillance using registry data: Results and recommendations for the Lithuanian national prostate cancer early detection programme. Eur J Cancer. 2015; 51(12):1630-7. DOI: 10.1016/j.ejca.2015.04.009. View

Carioli G, Malvezzi M, Rodriguez T, Bertuccio P, Negri E, La Vecchia C . Trends and predictions to 2020 in breast cancer mortality in Europe. Breast. 2017; 36:89-95. DOI: 10.1016/j.breast.2017.06.003. View

Autier P, Boniol M, La Vecchia C, LaVecchia C, Vatten L, Gavin A . Disparities in breast cancer mortality trends between 30 European countries: retrospective trend analysis of WHO mortality database. BMJ. 2010; 341:c3620. PMC: 2920378. DOI: 10.1136/bmj.c3620. View

Hery C, Ferlay J, Boniol M, Autier P . Quantification of changes in breast cancer incidence and mortality since 1990 in 35 countries with Caucasian-majority populations. Ann Oncol. 2008; 19(6):1187-94. DOI: 10.1093/annonc/mdn025. View

Rosenberg P, Check D, Anderson W . A web tool for age-period-cohort analysis of cancer incidence and mortality rates. Cancer Epidemiol Biomarkers Prev. 2014; 23(11):2296-302. PMC: 4221491. DOI: 10.1158/1055-9965.EPI-14-0300. View

Duggan C, Trapani D, Ilbawi A, Fidarova E, Laversanne M, Curigliano G . National health system characteristics, breast cancer stage at diagnosis, and breast cancer mortality: a population-based analysis. Lancet Oncol. 2021; 22(11):1632-1642. DOI: 10.1016/S1470-2045(21)00462-9. View

Malvezzi M, Carioli G, Bertuccio P, Negri E, La Vecchia C . Relation between mortality trends of cardiovascular diseases and selected cancers in the European Union, in 1970-2017. Focus on cohort and period effects. Eur J Cancer. 2018; 103:341-355. DOI: 10.1016/j.ejca.2018.06.018. View

Lopez-Abente G, Mispireta S, Pollan M . Breast and prostate cancer: an analysis of common epidemiological features in mortality trends in Spain. BMC Cancer. 2014; 14:874. PMC: 4251688. DOI: 10.1186/1471-2407-14-874. View

Everatt R, Kuzmickiene I, Intaite B, Anttila A . Effectiveness of the cervical cancer prevention programme: a case-control mortality audit in Lithuania. Eur J Cancer Prev. 2020; 29(6):504-510. DOI: 10.1097/CEJ.0000000000000603. View

10.

Bertuccio P, Santucci C, Carioli G, Malvezzi M, La Vecchia C, Negri E . Mortality Trends from Urologic Cancers in Europe over the Period 1980-2017 and a Projection to 2025. Eur Urol Oncol. 2021; 4(5):677-696. DOI: 10.1016/j.euo.2021.05.005. View

11.

Patasius A, Krilaviciute A, Smailyte G . Prostate Cancer Screening with PSA: Ten Years' Experience of Population Based Early Prostate Cancer Detection Programme in Lithuania. J Clin Med. 2020; 9(12). PMC: 7760278. DOI: 10.3390/jcm9123826. View

12.

Lopez-Otin C, Diamandis E . Breast and prostate cancer: an analysis of common epidemiological, genetic, and biochemical features. Endocr Rev. 1998; 19(4):365-96. DOI: 10.1210/edrv.19.4.0337. View

13.

van Poppel H, Roobol M, Chapple C, Catto J, Ndow J, Sonksen J . Prostate-specific Antigen Testing as Part of a Risk-Adapted Early Detection Strategy for Prostate Cancer: European Association of Urology Position and Recommendations for 2021. Eur Urol. 2021; 80(6):703-711. DOI: 10.1016/j.eururo.2021.07.024. View

14.

Wojtyla C, Bertuccio P, Wojtyla A, La Vecchia C . European trends in breast cancer mortality, 1980-2017 and predictions to 2025. Eur J Cancer. 2021; 152:4-17. DOI: 10.1016/j.ejca.2021.04.026. View

15.

Adliene D, Adlys G, Cerapaite R, Jonaitiene E, Cibulskaite I . Optimisation of X-ray examinations in Lithuania: start of implementation in mammography. Radiat Prot Dosimetry. 2005; 114(1-3):399-402. DOI: 10.1093/rpd/nch520. View

16.

Steponaviciene L, Briediene R, Vanseviciute R, Smailyte G . Trends in Breast Cancer Incidence and Stage Distribution Before and During the Introduction of the Mammography Screening Program in Lithuania. Cancer Control. 2019; 26(1):1073274818821096. PMC: 6327347. DOI: 10.1177/1073274818821096. View

17.

Ferlay J, Colombet M, Soerjomataram I, Dyba T, Randi G, Bettio M . Cancer incidence and mortality patterns in Europe: Estimates for 40 countries and 25 major cancers in 2018. Eur J Cancer. 2018; 103:356-387. DOI: 10.1016/j.ejca.2018.07.005. View

18.

Sebuodegard S, Botteri E, Hofvind S . Breast Cancer Mortality After Implementation of Organized Population-Based Breast Cancer Screening in Norway. J Natl Cancer Inst. 2019; 112(8):839-846. DOI: 10.1093/jnci/djz220. View

19.

Shoag J, Nyame Y, Gulati R, Etzioni R, Hu J . Reconsidering the Trade-offs of Prostate Cancer Screening. N Engl J Med. 2020; 382(25):2465-2468. PMC: 7491201. DOI: 10.1056/NEJMsb2000250. View

20.

Zhou C, Check D, Lortet-Tieulent J, Laversanne M, Jemal A, Ferlay J . Prostate cancer incidence in 43 populations worldwide: An analysis of time trends overall and by age group. Int J Cancer. 2015; 138(6):1388-400. PMC: 4712103. DOI: 10.1002/ijc.29894. View